Hyponatremia in a multiple myeloma patient treated with bortezomib
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2381
Abstract: Hematologists often encounter electrolyte disturbances such as hyponatremia during chemotherapy. Hyponatremia can be elicited by several mechanisms: renal or extra‐renal sodium loss, fluid hyper‐ infusion or excessive water intake, and endocrine disorders such as hypothyroidism,… read more here.
Keywords: patient treated; hyponatremia; sodium; day ... See more keywords
The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24032938
Abstract: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first… read more here.
Keywords: based regimens; treated bortezomib; mortality; early mortality ... See more keywords
Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.
Sign Up to like & getrecommendations! Published in 2017 at "Oncology letters"
DOI: 10.3892/ol.2017.5920
Abstract: In the present study, the effect of immunophenotyping on the prognoses of patients with multiple myeloma (MM) treated with bortezomib plus dexamethasone was investigated. The study involved 46 patients with MM, and analyzed the prognostic… read more here.
Keywords: effect immunophenotyping; patients treated; multiple myeloma; clinical effect ... See more keywords